Shire Plc has appointed Sylvie Gregoire as president of its human genetic therapies business, effective immediately. Ms Gregoire will be responsible for setting the strategic direction of the unit including managing pipeline growth, directing the R&D and portfolio management process and contributing to the overall strategic direction of Shire. She is replacing David Pendergast, who is retiring.
Ms Gregoire was most recently chair of the board of IDM Pharma and prior to that CEO of GlycoFi, a biotechnology company that was acquired by Merck & Co in May 2006. She will be based in Cambridge, Massachusetts, USA.
Shire is a speciality biopharmaceutical company which is based in Basingstoke, UK. It focuses on attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal and renal diseases.
Source:
Shire press release, 24 September 2007
Copyright 2007 Evernow Publishing Ltd